GeoVax Labs, Inc., a clinical-stage biotechnology company, is making significant strides in the development of its GEO-MVA vaccine for Mpox and smallpox, addressing the urgent need for diversified vaccine options amidst rising global cases. The company has received favorable regulatory feedback from the European Medicines Agency (EMA), setting the stage for an expedited path toward market access and commercialization. This development is critical as the world faces increasing public health threats from Mpox, with outbreaks reported across the U.S., Europe, and Africa.
The GEO-MVA vaccine, based on GeoVax’s modern platform, promises to enhance production capabilities, respond swiftly to epidemics, and reduce manufacturing costs. This platform aligns with U.S. biodefense objectives, offering a scalable solution to the current limitations in vaccine supply. David Dodd, GeoVax’s Chairman and CEO, highlighted the importance of diversifying stockpile planning to ensure public health security worldwide, positioning GEO-MVA as a complementary or alternative solution to existing vaccines.
In addition to the EMA’s support, GeoVax’s proposal under the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV) is under review. This program aims to fund scalable vaccine platforms, further emphasizing the strategic importance of GeoVax’s efforts in pandemic preparedness. The company’s advancements in vaccine development and manufacturing underscore the growing need for innovative solutions to combat infectious diseases and protect global health.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp
. The source URL for this press release is GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases.
